"Developing novel treatments for Dormant Cancers - targeting resistance, metastasis, and relapse."
Cancer cell dormancy is a major and as yet unaddressed mechanism of cancer survival and resistance. Until recently, the research efforts have been focused on combating the inherently resistant cancer cells and the acquired resistance, which develops over time on exposure to chemotherapeutics.
Felicitex is developing new therapies that are specifically target and kill cancer cells that use the dormancy state for their survival niche. Our therapies target both growing and dormant, otherwise non-responsive cancer cells with three therapeutically beneficial outcomes: first, kill dormant cancer cells and thereby eliminate their ability to develop resistant phenotype; second, decrease their metastatic potential; and third, eliminate cancer recurrence.
Cellular dormancy is a resting or “sleeping” state, denoted as the G0 state of the cell cycle. While being dormant, a cell is in a reversible low metabolic state. As a consequence, both transcription and translation processes are stalled and therefore these cells are resistant to damage by chemotherapeutics and targeted therapies.
Click above to view slides
© 2019 by Felicitex Therapeutics, Inc »« 27 Strathmore Road Natick, MA 01760 1-919-213-0025 (p) Click here to Contact Us!